Alzumab-L Injection 1.0 Injection in 1 vial

Alzumab-L Injection is given by intravenous infusion by a doctor or a nurse in a hospital or clinical setting. It is infused slowly over several hours. It is important to attend every scheduled dose and monitoring appointment since treatment response and safety are closely observed. The treatment schedule should be followed exactly as directed by the doctor.

Some people may experience infusion-related reactions during or after receiving Alzumab-L Injection, such as chills, fever, rash, cough, breathing difficulty, flushing, headache, or changes in blood pressure. These are more common during the first infusion and usually improve with slower administration and appropriate management.

Alzumab-L Injection should not be used in people who have had a severe allergic reaction to itolizumab or any ingredients in this product. Earlier starting treatment, patients must be screened for tuberculosis, and treatment should be used with caution in those with a history of recurrent infections or immunocompromised status. Vaccines should generally be avoided during therapy. Employ during pregnancy or breastfeeding is not recommended due to insufficient safety data.